Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/313924

Molecular Subtypes of Anaplastic Gliomas Identified with Somatic-Mutation and Pathway Based Gene Signature

Wardak, Z.·Park, S.·Zhu, H.·Choe, K.·Hwang, T. H.
View original source ↗Export metadata ↓

Abstract

PurposeAnaplastic gliomas constitute heterogeneous population with variable outcomes and no consensus on therapeutic approach. Molecular profiling may provide prognostication beyond clinical and pathologic factors and help guide treatment decisions.\n\nExperimental DesignThe Cancer Genome Atlas (TCGA) was utilized to derive a 39-gene low grade glioma-specific gene signature. Consensus clustering based on expression of the signature identified subgroups for 176 patients with anaplastic glioma from TCGA. Overall survival (OS) was analyzed for each subgroup. A total of 68 patients from Repository for Molecular Brain Neoplasia Data (REMBRANDT) were used as an independent validation dataset.\n\nResultsConsensus clustering separated the TCGA group into two distinct cohorts. The OS was significantly different between two subgroups, 20 vs. 67 months (p<0.001). On univariate analysis, the molecular subgroup, age, KPS, IDH1/2 mutation, 1p19q-co-deletion, chemotherapy, and use of both chemotherapy and radiation-therapy were significantly associated with OS. On multivariable analysis, the molecular subgroup remained significant with HR of 2.6 (p=.047, 95%CI [1.01-6.68]). In an independent validation with REMBRANDT, consensus clustering based on the signature successfully identified similarly poor prognostic subgroup with median survival of 14 months and concordance of expression patterns in 21 of the genes.\n\nConclusionExpression patterns of the 39 gene stratified anaplastic gliomas into two distinct subgroups with substantially different OS. This molecular prognostication was validated in an external dataset. Utilization of molecular subgroup, in addition to known prognostic factors may help define those requiring aggressive therapeutic intervention. Characteristic genes within the poor prognostic group may represent potential targets for therapeutic intensification.\n\nSource code and dataset used in this work is available for reviewers at: https://www.taehyunlab.org/ntripath\n\nImportance of the studyDespite the revolution of tailored therapy, anaplastic gliomas represent a category of tumors without clear treatment recommendations. While current prognostic factors help guide therapy recommendations, further refinement with the addition of molecular markers can help physicians with treatment recommendations. In this study, we developed a 39 gene prognostic gene signature by utilizing Pan-Cancer TCGA mutation profiles of over 5,000 patients across 19 different TCGA cancer types to stratify patients with anaplastic gliomas. We performed consensus clustering based on gene expression profiles of our 39-gene signature without any consideration of clinical factors or outcomes to TCGA anaplastic gliomas patients as well as an independent dataset and successfully identified two molecular subgroups with distinct clinical outcome. We found that subgroups have remarkably different survivals with a clear poor prognostic group. Furthermore, the poor prognostic group showed significant benefits for aggressive multimodality therapy, justifying the use of intensive therapy based on molecular stratification.

Explore related subjects

genomicsPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Wardak, Z., Park, S., Zhu, H., Choe, K., Hwang, T. H.. 2018-05-04. Molecular Subtypes of Anaplastic Gliomas Identified with Somatic-Mutation and Pathway Based Gene Signature. https://doi.org/10.1101/313924

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Shared and divergent features of the immune response to acute and chronic Trypanosoma cruzi infection in mice revealed by cardiac transcriptomics

Chagas disease is caused by infection with Trypanosoma cruzi and can result in chronic cardiomyopathy. However, the molecular programmes that define infected cardiac tissue, and how they change as the host-parasite relationship moves from acute pathogenic infection to long-term persistence, remain incompletely understood. Here, we used RNA sequencing to characterise host transcriptional responses in cardiac tissue during both acute and chronic infection in a mouse model. Cardiac parasite distribution was defined using bioluminescence imaging and histology, and RNA sequencing was performed on anatomically standardised cardiac tissue samples collected at both stages. Acute infection was associated with a broad interferon-driven immune activation, whereas during chronic infection this network contracted, with preservation of a tightly connected antigen presentation core centred on major histocompatibility complex genes and immunoproteasome components. Genes associated with extracellular matrix remodelling and fibrosis were not broadly activated. These findings indicate that reduced, but sustained immune activation, rather than widespread fibrotic transcriptional remodelling, represents a prominent feature of cardiac tissue in chronically infected mice. They identify a transition from an overtly inflammatory, pathogen-driven acute response to a more restricted chronic host-parasite equilibrium in which immune surveillance remains transcriptionally active despite very low and spatially intermittent cardiac infection. We identified a conserved 20-gene signature shared between acute and chronic stages. This overlap is consistent with continued or episodic parasite-derived stimulation and/or intrinsic host mechanisms that maintain cardiac immune surveillance. Thus, chronic T. cruzi infection can be viewed as a persistent host-parasite association in which biological coexistence does not imply benignity: immune containment and parasite persistence can occur alongside cumulative cardiac injury.

genomics↗
bioRxiv2026

Transcriptional contingency in the early hematopoiesis of inherited bone marrow failure syndromes

The inherited bone marrow failure syndromes (IBMFS) are a group of heterogeneous genetic diseases caused by germline pathogenic variants in genes involved in hematopoiesis and genomic integrity. Despite sharing common phenotypical manifestations that have aided opportune diagnosis, such as bone marrow failure, congenital malformations and an increased predisposition to develop cancer, little is known about the shared and distinctive transcriptional programs in their hematopoietic stem and progenitor cells compartment that underlie the clinical manifestations of each disease. In this work we have successfully integrated and analyzed the publicly available scRNAseq datasets of HSPCs from patients with Fanconi anemia (FA) and Telomere Biology disorders (TBD), as well as healthy controls. Once integrated, we performed quality control metrics, as well as batch effect correction using different methods. Through dimensionality reduction, cell clustering and cell type annotation we found distinctive gene expression profiles per syndrome and per cell type, as well as orchestrated gene expression profiles, including upregulation of inflammatory pathways and cell proliferation pathways. This work shows the integration of datasets from FA and TBD, two major IBMFS, and provides the basis for an accumulative, comparative, and integrated atlas of scRNAseq data from patients with IBMFS.

genomics↗
bioRxiv2026

Recurrent mitotic error and purifying selection shape chromosomal mosaicism across human tissues

Mosaic chromosomal alterations (mCAs) have been extensively studied in cancer and clonal hematopoiesis but less so in healthy solid tissues. Here, we characterized mCAs in 19 tissues across 25 donors (aged 42-89+ years) by analyzing >200x whole-genome sequencing data generated by the Somatic Mosaicism across Human Tissues (SMaHT) Network. Across 722 tissue samples, we identified 1,008 autosomal mCAs >1 Mb in length and ubiquitous losses of sex chromosomes. Surprisingly, the highest levels of Y chromosome loss in males (5-10% cell fraction in elderly donors) were observed in the lung, adrenal gland, and heart. These tissues also tended to experience more X loss in females, revealing a gradient of mitotic error burden across human tissues. Autosomal aneuploidies displayed distinct tissue-specific patterns indicative of negative selection against most events, except in the adrenal gland, in which low-level aneuploidy was pervasive. In contrast to the adrenal gland, testis rarely harbored aneuploidies but frequently experienced low-level copy-neutral loss of heterozygosity (CN-LOH), suggesting increased mitotic recombination in spermatogonial stem cells. Recurrent X chromosome losses within tissues of female donors exhibited allelic skews explained by a combination of genetic and epigenetic effects. Together, these results show that the chromosomal landscape of aging human tissues is shaped by genetics and recurrent mutations, most but not all of which are held in check by purifying selection.

genomics↗